WilliamJSlichenmyerMD

Oncology • Sherborn, MA

Physician

Join to view full profile

Dr. Slichenmyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Slichenmyer's full profile

Already have an account?

Office
121 Bogastow Brook Rd
Sherborn, MA 01770
Phone+1 508-650-3403
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1991 - 1994
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1987 - 1990
University of New Mexico School of MedicineResidency, Pathology-Anatomic and Clinical, 1984 - 1986
Case Western Reserve University School of MedicineClass of 1984

Certifications & Licensure

CT State Medical License 2004 - 2024
MD State Medical License 1991 - 2017

Publications & Presentations

PubMed

16 citations
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Monette M. Cotreau, Nicholas M. Siebers, James Miller, Strahs Andrew, William Slichenmyer> ;Clinical Pharmacology in Drug Development. 2015 Mar 1
5 citations
The effect of food on the pharmacokinetics of tivozanib hydrochloride.
Monette M. Cotreau, Lisa Massmanian, Strahs Andrew, William Slichenmyer, Dennis L. Vargo> ;Clinical Pharmacology in Drug Development. 2014 Mar 1
21 citations
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Mayer Fishman, Sandy Srinivas, Ralph J. Hauke, Robert J. Amato, Brooke Esteves, Monette M. Cotreau, Andrew Strahs, William Slichenmyer, P. Bhargava, Fairooz F. Kabbinavar> ;European Journal of Cancer. 2013 Sep 1
10 citations
Absorption, Metabolism, and Excretion of [14C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phas...
Monette M. Cotreau, Christine Hale, Lindsey Jacobson, Claudine S. Oelke, Strahs Andrew, Robert G. Kochan, Madhu Sanga, William Slichenmyer, Dennis L. Vargo> ;Clinical Pharmacology in Drug Development. 2012 Jul 1
87 citations
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Dmitry Nosov, Brooke Esteves, Oleg Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju Titus Chacko, Dinesh C. Doval, Andrew Strahs, William Slichenmyer, Pankaj Bhargava> ;Journal of Clinical Oncology. 2012 May 10
A phase I QTc study of tivozanib in patients with advanced solid tumors.
Chadha MK, Infante JR, Cotreau MM, Jacobson L, Strahs AL, Slichenmyer W, Vargo D, Moore KN> ;J. Clin. Oncol.. 2012-02-10
Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asia...
Mok T, Tan E, Park K, Jac J, Han M, Payumo FC, Credi M, McKee K, Cotreau MM, Bhargava P, Slichenmyer W> ;J. Clin. Oncol.. 2011-05-20
Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).
Nosov D, Bhargava P, Esteves WB, Strahs AL, Lipatov ON, Lyulko OO, Anischenko AO, Chacko RT, Doval D, Slichenmyer WJ> ;J. Clin. Oncol.. 2011-05-20
Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients ...
Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, Tan DS, Sun J, Jac J, Han M, Payumo FC, Credi M, McKee K, Cotreau MM, Bhargava P, Slichenmyer W> ;J. Clin. Oncol.. 2011-05-20
Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC).
Bhargava P, Esteves B, Al-Adhami M, Nosov D, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval D, Slichenmyer W> ;J. Clin. Oncol.. 2011-03-01
A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).
Motzer RJ, Bhargava P, Esteves B, Al-Adhami M, Slichenmyer W, Nosov D, Eisen T, Sternberg CN, Hutson TE> ;J. Clin. Oncol.. 2011-03-01
17 citations
Reanalysis of cancer drugs: old drugs, new tricks.
George F. Vande Woude, Gary J. Kelloff, Raymond W. Ruddon, Han-Mo Koo, Caroline C. Sigman, J. Carl Barrett, Robert W. Day, Adam P. Dicker, Robert S. Kerbel, David R. P...> ;Clinical Cancer Research. 2004 Jun 1
125 citations
CI-1033, a pan-erbB tyrosine kinase inhibitor.
William J Slichenmyer, William L. Elliott, David W. Fry> ;Seminars in Oncology. 2001 Oct 1
109 citations
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
William J Slichenmyer, David W. Fry> ;Seminars in Oncology. 2001 Oct 1
1 citations
Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer.
Mark Meyer, Erwin Jeong, Barbara Bolinger, Liang Chen, Peter F. Lenehan, William Slichenmyer, Ronald B. Natale> ;American Journal of Clinical Oncology. 2001 Apr 1
18 citations
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer.
Raymond C. Bergan, Doyle H Waggle, Stephen K Carter, Ivan Horak, William Slichenmyer, Michael Meyers> ;Urology. 2001 Apr 1
64 citations
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pai...
Eric J. Small, Alex McMillan, Mark Meyer, Liang Chen, William Slichenmyer, Peter F. Lenehan, Mario A. Eisenberger> ;Journal of Clinical Oncology. 2001 Mar 1
139 citations
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Plac...
Eric J. Small, Mark Meyer, M. Ernest Marshall, Leonard M. Reyno, Frederick J. Meyers, Ronald B. Natale, Peter F. Lenehan, Liang Chen, William Slichenmyer, Mario A. Eis...> ;Journal of Clinical Oncology. 2000 Apr 7
175 citations
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Anthony W. Tolcher, Steven Sugarman, Karen A. Gelmon, Roger B. Cohen, Mansoor N. Saleh, Claudine Isaacs, Leslie Young, Diane Healey, Nicole Onetto, William Slichenmyer> ;Journal of Clinical Oncology. 1999 Feb 1
91 citations
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Seamus O'Reilly, Eric K. Rowinsky, William Slichenmyer, Ross C. Donehower, Arlene A. Forastiere, David S. Ettinger, Tian Ling Chen, S E Sartorius, Louise B. Grochow> ;Journal of Clinical Oncology. 1996 Dec 1
55 citations
Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function
Seamus O'Reilly, Eric K. Rowinsky, William Slichenmyer, Ross C. Donehower, Arlene A. Forastiere, David S. Ettinger, Tian Ling Chen, S E Sartorius, Katherine M. Bowling...> ;Journal of the National Cancer Institute. 1996 Jun 19
6 citations
Recent clinical advances with camptothecin analogues.
William Slichenmyer, Ross C. Donehower> ;Cancer Treatment and Research. 1995 Jan 1
7 citations
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
William Slichenmyer, Ross C. Donehower, T L Chen, M K Bowling, William P. McGuire, Eric K. Rowinsky> ;Cancer Chemotherapy and Pharmacology. 1995 Jan 1
30 citations
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
William Slichenmyer, Eric K. Rowinsky, Louise B. Grochow, Scott H. Kaufmann, Ross C. Donehower> ;Cancer Chemotherapy and Pharmacology. 1994 Jan 1
280 citations
Loss of a p53-associated G1 Checkpoint Does Not Decrease Cell Survival following DNA Damage
William Slichenmyer, William G. Nelson, Robbert J. C. Slebos, Michael B. Kastan> ;Cancer Research. 1993 Sep 15
Join now to see all